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Abstract 
Context: Atypical antipsychotic agents (clozapine, olanzapine) have been linked to 
metabolic effects and acute pancreatitis.  
Case Report: We reviewed the inpatient and outpatient records of three patients who 
developed acute pancreatitis while being treated with olanzapine. The mean age of the 
patients was 37.7 years (range 18–54 years, 2 female, 1 male). No alternative cause of 
acute pancreatitis was found in two of the three patients. In the remaining patient, 
olanzapine may have contributed to acute pancreatitis in the setting of 
hypertriglyceridemia. Olanzapine was discontinued in all instances. Over a mean follow-
up of 14 months, one patient has had a relapsing course, but the remaining two patients 
have been symptom free without recurrence of acute pancreatitis.  
Conclusions: Our case series adds further support to the potential link between 
olanzapine use and acute pancreatitis. Close monitoring of metabolic parameters is 
suggested in patients treated with olanzapine. Alternative antipsychotic agents should 
be considered in patients at high risk for pancreatitis. 
Introduction 
Gallstones and alcohol are common etiologies of acute pancreatitis; rarer causes 
include hyperlipidemia, hypercalcemia, trauma, infection, and medications, among 
others. A definitive etiology is not immediately apparent in approximately 10% of cases, 
classified as idiopathic pancreatitis [1]. Increasing use of the MedWatch reporting system 
(http://www.fda.gov/medwatch) as well as heightened physician awareness have 
contributed to recognition of previously unknown adverse affects of routinely prescribed 
medications. Consequently, there is an emerging belief that some cases of presumed  
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idiopathic acute pancreatitis may be medication induced. Azathioprine, didanosine, 
pentamidine, and sulfonamides are most commonly implicated, but atypical 
antipsychotic agents have also been associated with acute pancreatitis [2]. 
Olanzapine (Zyprexa; Eli Lilly and Company, Indianapolis, Ind.), an atypical 
antipsychotic agent was developed after a precursor agent, clozapine, was found to be 
associated with agranulocytosis [3, 4]. Clozapine was initially linked to acute pancreatitis 
in 1992 [4, 5], and there has been concern that newer atypical antipsychotic agents, 
including olanzapine, could potentially also cause acute pancreatitis. At least three 
individual case reports have reported an association between olanzapine and acute 
pancreatitis [6–8], and a MedWatch surveillance system review [3] has also evaluated the 
connection. We report a series of three patients presenting with clinical and/or laboratory 
evidence of acute pancreatitis while being treated with olanzapine. 
Patients and Methods 
Over a period of 2 years, 3 patients (mean age 37.7 years, range 18–54 years, 2 females/1 male) 
referred for investigation and management of acute pancreatitis were noted to be taking olanzapine at 
presentation, and form the subjects for this case report. Inpatient and outpatient records were 
scrutinized to extract demographics, clinical presentation and hospital course. Outcome was assessed by 
office follow-up and telephone contact over a mean of 14 months (range 9–19 months). This case series 
was approved by the Human Studies Committee at Washington University School of Medicine. 
Informed consent was obtained from all patients. 
Case 1 
A 41-year-old Caucasian female presented with recurring episodes of acute pancreatitis dating back 
two years. She had no prior history of pancreatitis. She was taking olanzapine (5 mg/day) for depression, 
and the initiation of olanzapine preceded her first episode of pancreatitis by 3 months. She smoked half 
a pack of cigarettes a day, but she had no history of alcohol use. Over the next four months, she had 
several more episodes of acute pancreatitis culminating in a cholecystectomy. Pathologic examination of 
the cholecystectomy specimen did not reveal gallstones, sludge or cholecystitis. Three months after 
cholecystectomy, she developed two more episodes of pancreatitis, with lipase values peaking at 469 IU/l 
(normal range 0–60 IU/l). She was subsequently referred to our institution for further evaluation. 
Physical examination and routine laboratory testing did not reveal any abnormalities. Serum calcium 
level and lipid panel were within normal limits. A CT scan of the abdomen demonstrated mild 
dilatation of the extrahepatic bile ducts and an absent gallbladder, but no evidence of pancreas divisum 
or other structural pancreatic or biliary abnormality. An endoscopic ultrasound showed no causes for 
acute pancreatitis. Olanzapine was implicated and the medication discontinued. Over 19 months of 
follow-up, she has had relapsing abdominal pain, with at least one documented episode of acute 
pancreatitis. However, her pain episodes have been less frequent and less intense after olanzapine was 
discontinued. 
Case 2 
An 18-year-old African American female with childhood seizures and bipolar disorder was treated 
with olanzapine (10 mg/day) and sertraline. She presented with mid abdominal and left lower quadrant 
pain approximately two years later. She had no prior history of pancreatitis. She smoked a half pack of 
cigarettes a day and drank alcohol only on a social basis. On presentation, she had clinical and 
laboratory evidence of pancreatitis, with amylase of 195 IU/l (normal range 28–100 IU/l) and lipase of 
418 IU/l (normal range 0–60 IU/l). Olanzapine was discontinued. Her course was complicated by 
Clostridium difficile colitis, and she required 19 days of inpatient management and total parenteral 
nutrition, but recovered fully. When seen several weeks later at our institution, her amylase and lipase 
levels had normalized. Work-up included an abdominal ultrasound, a CT scan of the abdomen, and an 
MRCP, all of which were normal and did not reveal a potential alternate explanation for her  
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pancreatitis. Olanzapine associated pancreatitis was considered, and she was counseled not to resume 
olanzapine. She has had no further episodes of pancreatitis off olanzapine in 14 months of follow-up. 
Case 3 
A 54-year-old Caucasian male with schizoaffective disorder treated with olanzapine (20 mg/day) for 
at least one year was admitted to a local hospital with three weeks of vomiting, abdominal pain, and 
poor appetite. Although his past history suggested hypertriglyceridemia with a pretreatment serum 
triglyceride value of 500 mg/dl, he had been compliant with fenofibrate therapy for the previous 18 
months. He smoked one pack of cigarettes per day, and only consumed small amounts of alcohol 
socially. His other medications upon presentation included ziprasidone, mirtazapine, clonazepam and 
venlafaxine. On examination he was found to be jaundiced. An abdominal ultrasound revealed no 
gallstones, but the proximal common bile duct measured 9 mm in diameter. A CT scan demonstrated 
an inflammatory process at the pancreatic head, with peripancreatic inflammation. Olanzapine was 
discontinued and the patient referred to our institution for further management. Amylase, lipase, and 
CA 19-9 values were within normal limits. An ERCP revealed a distal common bile duct stricture with 
proximal ductal dilation. Endoscopic sphincterotomy, brushing of the stricture for cytology, and stent 
placement were performed; cytology was unremarkable. Subsequently, an endoscopic ultrasound 
revealed an inflammatory process in the head of the pancreas with surrounding lymphadenopathy. 
Olanzapine associated pancreatitis was considered, and the patient was advised not to resume this 
medication. The stricture resolved with conservative management. A repeat CT scan 6 months later 
revealed resolution of the pancreatic inflammation. No further episodes of pancreatitis have occurred 
over 9 months follow-up. 
Discussion 
In this report, we describe a series of three patients with idiopathic acute pancreatitis in 
temporal association with the use of olanzapine, an atypical antipsychotic agent. Careful 
and exhaustive clinical and laboratory evaluation failed to reveal a clear alternate etiology 
for acute pancreatitis in two patients. The remaining patient was under appropriate and 
adequate pharmacologic therapy for elevated triglycerides, and acute pancreatitis did not 
occur until after olanzapine was introduced. The authors believe that olanzapine was very 
likely a precipitating factor for acute pancreatitis in all these patients, especially since 
episodes diminished or resolved after the medication was withheld. While this association 
is difficult to conclusively establish, the possibility of this severe side effect may prompt 
additional caution in using olanzapine. 
Atypical antipsychotic agents are used to treat a variety of conditions ranging from 
schizophrenia and acute mania to bipolar disorder and agitation, and off label uses for 
other psychiatric conditions are common. Clozapine was the first to be introduced in 
1989, but agranulocytosis as a side effect has significantly curtailed its use. Olanzapine 
was developed as a replacement without the risk for agranulocytosis, and was approved by 
the Food and Drug Administration for clinical use in 1996. Commonly reported side 
effects with this medication consist of sleepiness, dry mouth, dizziness, restlessness, 
constipation, upset stomach, weight gain, increased appetite, and tremor. Potential severe 
adverse effects include extrapyramidal signs and symptoms [9]. A recent FDA review of 
17 placebo-controlled studies of elderly demented patients treated with atypical 
antipsychotics suggested increased overall mortality with these agents when compared 
with placebo-treated groups, although the common causes of death were not different 
between the two groups [10]. Nevertheless, a black box warning was issued.  
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From a gastroenterologist’s standpoint, acute pancreatitis is the most concerning 
association of atypical antipsychotic agents. Acute pancreatitis associated with clozapine 
was recognized when it was first introduced [4, 5]. Since 2000, there have been four cases 
of olanzapine associated pancreatitis reported in the literature [6–8]. The interval between 
initiation of olanzapine and onset of pancreatitis can be long, and has been reported to 
range from a few weeks to over 18 months [6–8], consistent with our observations. 
Therefore, patients who tolerate the medication in the short term could still develop 
pancreatitis after many months or even years. Our patients suffered from some of the 
severe complications of pancreatitis, including prolonged course, inflammatory 
phlegmon, and a relapsing course, suggesting that clinical course can be rough and 
potentially fatal. However, it is possible that the cases we describe represent the severe end 
of the spectrum of acute pancreatitis associated with olanzapine, since our institution 
caters to tertiary care. 
Atypical antipsychotic agents are thought to exert their pharmacologic action through 
antagonism of dopamine and serotonin receptors, which results in lesser likelihood of 
extrapyramidal reactions compared to typical antipsychotics [11]. The mechanism for 
pancreatitis, however, is not clear. Ongoing research is focused on understanding the 
action of olanzapine on dopamine, serotonin, histamine, gamma-aminobutyric acid and 
adrenergic receptors in the mediation of adverse effects [12]. Atypical antipsychotic 
agents have been associated with weight gain, glucose intolerance, and development of 
type 2 diabetes in epidemiologic studies [13], and consequently, effects on glucose, 
triglyceride, insulin, and leptin metabolism are thought to contribute to adverse effects 
including pancreatitis [7]. The relationship between the global metabolic effects of 
atypical antipsychotics, including impaired glucose homeostasis, and direct pancreatic 
injury resulting in pancreatitis may reveal a common mechanism underlying both of 
these adverse effects. One longitudinal study over a five-year period documented an 
approximate doubling in serum triglyceride levels in patients treated with clozapine [14]. 
Similar increases in serum triglycerides have also been reported with olanzapine use [15, 
16]. One of our patients had elevated triglyceride levels, but did not develop acute 
pancreatitis until olanzapine was initiated; further, he did not have a recurrence of acute 
pancreatitis after olanzapine was discontinued. This may suggest that patients with 
hypertriglyceridemia may further raise their triglyceride levels with these agents, thereby 
having a higher likelihood of pancreatitis when given this medication. If this hypothesis is 
true, patients being started on olanzapine may need to be screened for 
hypertriglyceridemia, and the medication avoided if this is found. It is unclear if patients 
with normal triglyceride levels will develop hypertriglyceridemia while on olanzapine, and 
further studies are needed. There is also mention in the literature of olanzapine acting 
synergistically with other known etiologic factors in causing acute pancreatitis, for 
instance, alcohol abuse [8]. 
Though little is known about olanzapine-associated pancreatitis, much study has been 
done on drug induced hepatotoxicity [17]. In the case of the liver, mechanisms of drug 
induced injury include disruption of intracellular calcium homeostasis, disruption of 
actin filaments, covalent modification of intracellular proteins, altered immunogenicity, 
activation of apoptosis, and mitochondrial disruption. It remains to be determined 
whether antipsychotic medication effects on the pancreas are mediated through direct  
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mechanisms as in the liver, or whether the effects are a consequence of global metabolic 
changes. 
More study is required to further evaluate the effects of atypical antipsychotics on 
pancreatic function and pancreatitis. In addition to close monitoring for development of 
obesity and impaired glucose metabolism, it is prudent to exercise caution in treating 
patients at high risk for pancreatitis with these medications. This includes patients with 
elevated triglycerides, a prior history of pancreatitis, alcohol abuse, metabolic 
abnormalities and medications that increase the risk of pancreatitis. We agree with the 
suggestion by Waage et al. that patients on olanzapine should have frequent monitoring 
of blood work including pancreatic enzymes, particularly if they have one or more of the 
above risk factors for pancreatitis [7]. Patients who have tolerated the medication in the 
short term should not be viewed as being free from risk of pancreatitis. Furthermore, 
when patients present with pancreatitic and biliary disease of unclear etiology, careful 
evaluation and a high index of suspicion are necessary to determine if medications such as 
olanzapine may be contributing to the etiology of pancreatitis. 
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